ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 121 for:    regeneron AND VEGF Trap-Eye

Intravitreal Aflibercept Injection for Radiation Retinopathy Trial (ARRT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03085784
Recruitment Status : Recruiting
First Posted : March 21, 2017
Last Update Posted : May 15, 2018
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Amy C Schefler, MD, Greater Houston Retina Research

Brief Summary:
The ARRT trial will assess the safety and efficacy of 2mg aflibercept for the treatment of radiation retinopathy, including maculopathy and optic neuropathy over 52 weeks.

Condition or disease Intervention/treatment Phase
Radiation Retinopathy Drug: Aflibercept Phase 2

Detailed Description:

Approximately 30 eyes will be randomized (1:1 ratio) into either Group 1 or Group 2. Slit lamp exam and Indirect ophthalmoscopy will be performed at every study visit, where retinopathy level will be assessed. SD-OCT will be performed at each visit. Fluorescein angiogram will be performed at screen, week 26 and week 52. All other imaging studies will be standard of care at the discretion of the investigator.

This trial will compare the results of 2 groups, with different treatment intervals, to assess the safety of intravitreal Aflibercept injections (IAI) for the treatment of radiation retinopathy. Patients in each group will be followed for a total of 52 weeks.

Group 1: 15 Patients will receive a loading dose of 3 IAI. They will receive 2 mg IAI at screening/baseline, week 4, week 8, and week 12. A follow-up visit will occur at week 12. If the extension criteria are met, the patient will be extended by 2 weeks. The patient will continue to be followed per the treat and extend protocol described below.

Group 2: Patients will not receive a loading dose. They will receive 2 mg IAI at screening/baseline followed by a visit at week 4. At week 4, if the extension criteria are met, the patient will be extended by 2 weeks. The patient will continue to be followed per the treat and extend protocol described below.

Treat & Extend Protocol Patients can be extended as long as they meet the following criteria -

  • Absence of retinal fluid (resolution of intraretinal and subretinal fluid on SD-OCT; Small intraretinal cysts that do not distort foveal contour on SD-OCT are acceptable and can be considered "dry".) AND
  • Less than 5 ETDRS letter loss from previous visit due to new or persistent retinal edema.

IAI will be rendered at every visit (treatment at the week 26 mandatory visit will be administered based on the treat and extend status), no earlier than 4 days before the target date and no later than 4 days after the target date. Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, the treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached.

All patients will have a mandatory study visit at Week 52 (final study visit). No study treatment will be administered after week 50 or at a study termination visit. If a patient receives treatment after week 48, they will return 4 weeks after the last clinic visit for the final study visit (instead of at week 52).


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intravitreal Aflibercept Injection (IAI) for Radiation Retinopathy Trial (ARRT)
Actual Study Start Date : July 5, 2017
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Loading Dose

15 Patients will receive 4, 2 mg IVT Aflibercept (IAI) a month apart, screening/baseline, weeks 4, 8, & 12. At week 12, patient will be followed & treated per treat & extend protocol.

Treat & Extend Protocol entails patients being extended as long as:

  • Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered "dry".) AND
  • < 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.

Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached.

Drug: Aflibercept
The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
Other Name: Eylea

Experimental: Treat and Extend

15 Patients will receive 2 mg IVT Aflibercept (IAI) at screening/baseline followed by a visit at week 4. At week 4, patient will be treated & followed per the treat & extend protocol.

Treat & Extend Protocol entails patients being extended as long as:

  • Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered "dry".) AND
  • < 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.

Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached.

Drug: Aflibercept
The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
Other Name: Eylea




Primary Outcome Measures :
  1. Safety of intravitreal Aflibercept for the treatment of radiation retinopathy - Assessed by incidence of adverse events. [ Time Frame: 52 Weeks ]
    The primary objective of the study is to assess the safety of 2 mg intravitreal Aflibercept injections (IAI) for the treatment of radiation retinopathy including maculopathy and optic neuropathy. Assessed by incidence of adverse events.


Secondary Outcome Measures :
  1. Resolution of macular edema (CRT) [ Time Frame: 52 Weeks ]
    Resolution of macular edema as measured by mean change in central retinal thickness

  2. Resolution of macular edema (% dry) [ Time Frame: 52 Weeks ]
    Resolution of macular edema as measured by % of patients who achieve a dry macula

  3. Stabilization and improvement in visual acuity [ Time Frame: 52 Weeks ]
    Stabilization and improvement in visual acuity as measured by the mean change in Early Treatment Diabetic Retinopathy Study best-corrected visual acuity

  4. Dosing frequency of intravitreal aflibercept injections [ Time Frame: 52 Weeks ]
    Dosing frequency of IAI as measured by number of injections

  5. Incidence of neovascularization, vitreous hemorrhage, and need for vitrectomy [ Time Frame: 52 Weeks ]
    Percentage of patients avoiding the development of increased neovascularization, vitreous hemorrhage, and need for vitrectomy

  6. Resolution of retinal hemorrhage, retinal exudates, optic disc edema, and capillary non-perfusion [ Time Frame: 52 Weeks ]
    Percentage of patients with resolution of retinal hemorrhages, retinal exudates, optic disc edema, capillary non-perfusion



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age > 18 years of age
  2. Clinically identifiable radiation retinopathy with evidence of fluid on SD-OCT causing vision loss in the study eye
  3. Undergone either ocular or orbital radiation for any primary ocular or orbital cancer within clinical evidence of having radiation retinopathy
  4. Willing and able to comply with clinic visits and study-related procedures
  5. Provide signed informed consent

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from the study:

  1. Metastatic cancer or any active primary cancer, at time of enrollment
  2. Prior treatment with anti VEGF in the study within 60 days of screen in the study eye
  3. Prior intravitreal or subconjunctival treatment with cortical steroids within 90 days of screen in the study eye
  4. Macular ischemia (defined as greater than 5 disc areas), as assessed by the investigator
  5. Media opacity obscuring a view of the fundus or any other reason for vision loss other than radiation retinopathy.
  6. Evidence of infectious ocular infection, in the study eye, at time of screening
  7. Pregnant or breast-feeding women
  8. Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception start of the first treatment, during the study, and for at least 3 months after the last dose. Adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly.

    • Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03085784


Contacts
Contact: Chelsey Moore 713-394-7575 chelsey.moore@houstonretina.com
Contact: Cassie Cone, BA 713-394-7537 cassandra.cone@houstonretina.com

Locations
United States, Texas
Retina Consultants of Houston/Texas Medical Center Recruiting
Houston, Texas, United States, 77030
Contact: Chelsey Moore    713-524-3434    chelsey.moore@houstonretina.com   
Contact: Cassie Cone, BA    713-524-3434    cassandra.cone@houstonretina.com   
Sub-Investigator: David M Brown, MD         
Sub-Investigator: Matthew S Benz, MD         
Sub-Investigator: Charles C Wykoff, PhD, MD         
Sub-Investigator: Tien P Wong, MD         
Sub-Investigator: Rosa Y Kim, MD         
Principal Investigator: Amy C Schefler, MD         
Sub-Investigator: James C Major, MD         
Sub-Investigator: Richard H Fish, MD         
Sub-Investigator: Eric Chen, MD         
Sub-Investigator: Christopher R Henry, MD         
Retina Consultants of Houston Recruiting
Katy, Texas, United States, 77494
Contact: Chelsey Moore    713-524-3434    chelsey.moore@houstonretina.com   
Contact: Cassie Cone, BA    713-524-3434    cassandra.cone@houstonretina.com   
Sub-Investigator: Charles C Wykoff, PhD, MD         
Sub-Investigator: David M Brown, MD         
Sub-Investigator: Matthew S Benz, MD         
Sub-Investigator: Tien P Wong, MD         
Sub-Investigator: James C Major, PhD, MD         
Principal Investigator: Amy C Schefler, MD         
Sub-Investigator: Christopher R Henry, MD         
Sub-Investigator: Eric Chen, MD         
Sub-Investigator: Ankoor R Shah, MD         
Retina Consultants of Houston/The Woodlands Recruiting
The Woodlands, Texas, United States, 77384
Contact: Melisa Bocanegra    713-394-7534    melisa.bocanegra@houstonretina.com   
Sub-Investigator: David M Brown, MD         
Sub-Investigator: Tien P Wong, MD         
Sub-Investigator: Matthew S Benz, MD         
Sub-Investigator: James C Major, MD         
Sub-Investigator: Richard H Fish, MD         
Sub-Investigator: Charles C Wykoff, MD         
Sub-Investigator: Eric Chen, MD         
Principal Investigator: Amy C Schefler, MD         
Sponsors and Collaborators
Amy C Schefler, MD
Regeneron Pharmaceuticals
Investigators
Principal Investigator: Amy C Schefler, MD Retina Consultants Houston
  Study Documents (Full-Text)

Documents provided by Amy C Schefler, MD, Greater Houston Retina Research:
Informed Consent Form  [PDF] May 3, 2017


Publications:

Responsible Party: Amy C Schefler, MD, Principal Investigator, Greater Houston Retina Research
ClinicalTrials.gov Identifier: NCT03085784     History of Changes
Other Study ID Numbers: ARRT
First Posted: March 21, 2017    Key Record Dates
Last Update Posted: May 15, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Retinal Diseases
Eye Diseases